XML 47 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Nov. 30, 2017
TargetAntigen
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue   $ 50,000 $ 404,000 $ 50,000 $ 523,000
Surface Oncology, Inc.          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Number of target antigens against which antibodies are to be identified and selected | TargetAntigen 2        
Service fee payments/revenue   0 4,000 0 123,000
Revenue     400,000   400,000
Surface Oncology, Inc. | Exercise of Product Option          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue     300,000   300,000
Surface Oncology, Inc. | Exclusive Product License          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue     $ 100,000   $ 100,000
Annual maintenance fee   $ 50,000   $ 50,000  
Surface Oncology, Inc. | Minimum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Term of research program 9 months        
Surface Oncology, Inc. | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Term of research program 12 months